Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M.

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. No abstract available.

PMID:
29359798
2.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M.

Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15.

3.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Minetto P, Guolo F, Clavio M, De Astis E, Colombo N, Grasso R, Fugazza G, Sessarego M, Lemoli RM, Gobbi M, Miglino M.

Leuk Res. 2015 Aug;39(8):866-73. doi: 10.1016/j.leukres.2015.04.011. Epub 2015 Apr 27.

PMID:
26012361
4.

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.

Aliano S, Cirmena G, Fugazza G, Bruzzone R, Palermo C, Sessarego M.

Leuk Res Rep. 2013 Aug 31;2(2):75-8. doi: 10.1016/j.lrr.2013.07.004. eCollection 2013.

5.

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

Cagnetta A, Garuti A, Marani C, Cea M, Miglino M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, Grasso R, Nencioni A, Gobbi M, Patrone F.

Curr Cancer Drug Targets. 2013 Sep;13(7):779-90. Review.

PMID:
23906053
6.

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Marani C, Clavio M, Grasso R, Colombo N, Guolo F, Kunkl A, Ballerini F, Giannoni L, Ghiggi C, Fugazza G, Ravetti JL, Gobbi M, Miglino M.

Leuk Res. 2013 Dec;37(12):1606-11. doi: 10.1016/j.leukres.2013.07.005. Epub 2013 Jul 23.

PMID:
23891447
7.

Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated from blood, Italy.

Migliavacca R, Espinal P, Principe L, Drago M, Fugazza G, Roca I, Nucleo E, Bracco S, Vila J, Pagani L, Luzzaro F.

Diagn Microbiol Infect Dis. 2013 Feb;75(2):180-6. doi: 10.1016/j.diagmicrobio.2012.11.002. Epub 2012 Dec 21.

PMID:
23265293
8.

Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center.

Espinal P, Fugazza G, López Y, Kasma M, Lerman Y, Malhotra-Kumar S, Goossens H, Carmeli Y, Vila J.

Antimicrob Agents Chemother. 2011 Nov;55(11):5396-8. doi: 10.1128/AAC.00679-11. Epub 2011 Aug 8.

9.

Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy.

Mezzatesta ML, D'Andrea MM, Migliavacca R, Giani T, Gona F, Nucleo E, Fugazza G, Pagani L, Rossolini GM, Stefani S.

Clin Microbiol Infect. 2012 Feb;18(2):160-6. doi: 10.1111/j.1469-0691.2011.03527.x. Epub 2011 Jul 1.

10.

p38 MAPK and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cells.

Spallarossa P, Altieri P, Barisione C, Passalacqua M, Aloi C, Fugazza G, Frassoni F, Podestà M, Canepa M, Ghigliotti G, Brunelli C.

PLoS One. 2010 Dec 20;5(12):e15583. doi: 10.1371/journal.pone.0015583.

11.

CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia.

Guastadisegni MC, Lonoce A, Impera L, Di Terlizzi F, Fugazza G, Aliano S, Grasso R, Cluzeau T, Raynaud S, Rocchi M, Storlazzi CT.

Leukemia. 2010 Aug;24(8):1516-9. doi: 10.1038/leu.2010.106. Epub 2010 Jun 3. No abstract available.

PMID:
20520637
12.

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

Cea M, Cirmena G, Garuti A, Rocco I, Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, Gobbi M, Nencioni A, Ballestrero A, Patrone F.

Leuk Res. 2010 Sep;34(9):e240-2. doi: 10.1016/j.leukres.2010.03.036. Epub 2010 May 5. No abstract available.

PMID:
20447687
13.

Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates.

Nucleo E, Fugazza G, Migliavacca R, Spalla M, Comelli M, Pagani L, Debiaggi M.

New Microbiol. 2010 Jan;33(1):37-45.

14.

Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii.

Nucleo E, Steffanoni L, Fugazza G, Migliavacca R, Giacobone E, Navarra A, Pagani L, Landini P.

BMC Microbiol. 2009 Dec 22;9:270. doi: 10.1186/1471-2180-9-270.

15.

Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2.

Spallarossa P, Altieri P, Aloi C, Garibaldi S, Barisione C, Ghigliotti G, Fugazza G, Barsotti A, Brunelli C.

Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2169-81. doi: 10.1152/ajpheart.00068.2009. Epub 2009 Oct 2.

16.

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M.

Blood. 2009 Dec 3;114(24):4939-43. doi: 10.1182/blood-2009-07-229864. Epub 2009 Oct 1.

PMID:
19797518
17.

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.

Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, Bacigalupo A, Ravazzolo R, Ballestrero A, Sessarego M.

Cancer Genet Cytogenet. 2008 Jun;183(2):105-8. doi: 10.1016/j.cancergencyto.2008.02.005.

PMID:
18503828
18.

HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22).

Aliano S, Cirmena G, Garuti A, Fugazza G, Bruzzone R, Rocco I, Malacarne M, Ballestrero A, Sessarego M.

Cancer Genet Cytogenet. 2007 Sep;177(2):115-9.

PMID:
17854665
19.

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.

Miglino M, Grasso R, Varaldo R, Fugazza G, Colombo N, Clavio M, Canepa L, Garuti A, Ibatici A, Pierri I, Ballerini F, Sessarego M, Gobbi M.

Leuk Lymphoma. 2006 Jul;47(7):1348-51.

PMID:
16923567
20.

Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia.

Fugazza G, Garuti A, Marchelli S, Miglino M, Bruzzone R, Gatti AM, Castello S, Sessarego M.

Cancer Genet Cytogenet. 2005 Dec;163(2):173-5.

PMID:
16337863
21.

Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.

Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, Gobbi M, Frassoni F, Sessarego M.

J Exp Clin Cancer Res. 2004 Jun;23(2):295-9.

PMID:
15354415
22.

Interferon-alpha protects Philadelphia-negative progenitors from exhaustion in chronic myeloid leukemia patients with cytogenetic response.

Frassoni F, Podestà M, Piaggio G, Rosti V, Pitto A, Soracco M, Figari O, Vassallo F, Fugazza G, Bergamaschi G, Bacigalupo A, Sessarego M, Cazzola M.

Hematol J. 2001;2(1):26-32.

PMID:
11920230
23.

Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.

Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G, Bregante S, Frassoni F, Sessarego M, Fugazza G, Di Stefano F, Pitto A, Bacigalupo A.

Br J Haematol. 2000 Jun;109(4):716-21.

PMID:
10929020
24.

Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis.

Podestà M, Piaggio G, Sessarego M, Pitto A, Figari O, Soracco M, Carella AM, Dejana A, Rosti V, Fugazza G, Ravera G, Lerma E, Cazzola M, Bacigalupo A, Frassoni F.

Exp Hematol. 2000 Feb;28(2):210-5.

PMID:
10706077
25.

Peripheral plasma amino acid abnormalities in rehabilitation patients with severe brain injury.

Aquilani R, Viglio S, Iadarola P, Guarnaschelli C, Arrigoni N, Fugazza G, Catapano M, Boschi F, Dossena M, Pastoris O.

Arch Phys Med Rehabil. 2000 Feb;81(2):176-81.

PMID:
10668771
26.

Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.

Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A.

Haematologica. 2000 Jan;85(1):35-9.

27.

Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy.

Piaggio G, Podestà M, Pitto A, Sessarego M, Figari O, Fugazza G, Benvenuto F, Bruno B, Van Lint MT, Truini M, Frassoni F, Bacigalupo A.

Br J Haematol. 1999 Dec;107(3):505-11.

PMID:
10583249
28.

Changes of chromatin condensation in one patient with ataxia telangiectasia disorder: a structural study.

Vergani L, Fugazza G, Chessa L, Nicolini C.

J Cell Biochem. 1999 Dec 15;75(4):578-86.

PMID:
10572241
29.

Relapse after allogeneic BMT for chronic myeloid leukemia (CML) may be sustained by a small number of leukemic 'stem cells': a hypothesis.

Frassoni F, Podestà M, Piaggio G, Pitto A, Figari O, Soracco M, Lint M, Fugazza G, Sessarego M, Bacigalupo A.

Bone Marrow Transplant. 1999 Sep;24(6):689-91.

30.

Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time.

Frassoni F, Podestà M, Piaggio G, Rosti V, Pitto A, Benvenuto F, Figari O, Vassallo F, Carella AM, Zikos P, Bergamaschi G, Fugazza G, Sessarego M, Cazzola M.

Br J Haematol. 1999 Mar;104(3):538-45.

PMID:
10086792
31.
32.

Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse.

Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S, Berisso G, Mordini N, Incagliato M, Fugazza G, Sessarego M, Bacigalupo A.

Haematologica. 1998 Oct;83(10):896-903.

33.

Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization.

Sessarego M, Fugazza G, Gobbi M, Bruzzone R, Bisio R, Ghio R, Patrone F.

Cancer Genet Cytogenet. 1998 Oct 15;106(2):110-5.

PMID:
9797774
34.

Delineation of genomic regions in chromosome band 7q22 commonly deleted in myeloid leukemias.

Fischer K, Brown J, Scherer SW, Schramm P, Stewart J, Fugazza G, Pascheberg U, Peter W, Tsui LC, Lichter P, Döhner H.

Recent Results Cancer Res. 1998;144:46-52. Review. No abstract available.

PMID:
9304706
35.

High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study.

Sessarego M, Fugazza G, Balleari E, Bruzzone R, Ballestrero A, Patrone F.

Cancer Genet Cytogenet. 1997 Sep;97(2):161-4.

PMID:
9283601
36.

Amplified c-MYC sequences localized by fluorescence in-situ hybridization on double minute chromosomes in acute myeloid leukemias.

Fugazza G, Bruzzone R, Puppo L, Patrone F, Sessarego M.

Leuk Res. 1997 Aug;21(8):703-9.

PMID:
9379677
37.

Duplication of the der(13)t(12;13)(p13;q14) in chronic myelomonocytic leukemia.

Fugazza G, Cerri R, Bruzzone R, Patrone F, Sessarego M.

Haematologica. 1997 May-Jun;82(3):336-7.

38.

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.

Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, Figari O, Benvenuto F, Sessarego M, Fugazza G, Carlier P, Valbonesi M.

Bone Marrow Transplant. 1997 May;19(9):927-32.

39.

Spontaneous exodus of high numbers of normal early progenitor cells (Ph-negative LTC-IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease.

Podestà M, Piaggio G, Sessarego M, Pitto A, Benvenuto F, Vassallo F, Fugazza G, Carella AM, Frassoni F.

Br J Haematol. 1997 Apr;97(1):94-8.

PMID:
9136946
40.

Cytogenetic abnormalities in patients with severe aplastic anemia.

Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, Bregante S, Valeriani A, Mordini N, Lamparelli T, Gualandi F, Occhini D, Bacigalupo A.

Haematologica. 1996 Sep-Oct;81(5):418-22.

42.

Loss of telomeric sequences in a ring derived from chromosome 8 in refractory anemia with excess of blasts in transformation.

Fugazza G, Bruzzone R, Sessarego M.

Cancer Genet Cytogenet. 1996 Jul 1;89(1):31-3.

PMID:
8689606
43.

[Decubitus ulcer in the calcaneus region: rapid development, difficult recovery].

Fugazza G, Bona F.

Minerva Med. 1996 Mar;87(3):89-92. Italian.

PMID:
8668293
44.

Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation.

Sessarego M, Fugazza G, Canepa L, Bacigalupo A, Bruzzone R, Patrone F.

Leuk Res. 1995 Dec;19(12):921-5.

PMID:
8632661
45.

[The treatment of decubitus lesions].

Fugazza G, Moroni S, Bona F.

Riv Eur Sci Med Farmacol. 1995 Sep-Oct;17(5):197-202. Italian.

PMID:
8766788
46.

Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization.

Fugazza G, Bruzzone R, Dejana AM, Gobbi M, Ghio R, Patrone F, Rattenni S, Sessarego M.

Leukemia. 1995 Jan;9(1):109-14.

PMID:
7845004
47.
48.

Chromosome derived from translocation(1;17) retains alphoid sequences of both chromosomes involved.

Fugazza G, Bruzzone R, Sessarego M.

Cancer Genet Cytogenet. 1994 Nov;78(1):7-9.

PMID:
7987809
49.

Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes.

Mareni C, Sessarego M, Montera M, Fugazza G, Origone P, D'Amato E, Lerza R, Pistoia V, Scarra GB.

Leuk Lymphoma. 1994 Sep;15(1-2):135-41.

PMID:
7858491
50.

Variant Philadelphia chromosome translocations are frequently associated with additional structural abnormalities.

Sessarego M, Fugazza G, Bruzzone R, Patrone F.

Cancer Genet Cytogenet. 1994 Mar;73(1):57-9.

PMID:
8174075

Supplemental Content

Loading ...
Support Center